BIOFRONTERA AG (B8FK.DE) Stock Price, Forecast & Analysis
Europe • Frankfurt Stock Exchange • FRA:B8FK • DE000A4BGGM7
B8FK.DE Key Statistics, Chart & Performance
The current stock price of B8FK.DE is 2.38 EUR. In the past month the price decreased by -6.67%. In the past year, price increased by 1.06%.
B8FK.DE Technical Analysis
B8FK.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to B8FK.DE. While B8FK.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
B8FK.DE Financial Highlights
Over the last trailing twelve months B8FK.DE reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -8.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.27% | ||
| ROE | -18% | ||
| Debt/Equity | 0.01 |
B8FK.DE Forecast & Estimates
For the next year, analysts expect an EPS growth of 124.55% and a revenue growth 22.18% for B8FK.DE
B8FK.DE Ownership
B8FK.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.6 | 195.928B | ||
| SAN | SANOFI | 9.68 | 195.831B | ||
| SNW | SANOFI | 9.58 | 195.662B | ||
| MRK | MERCK KGAA | 14.41 | 53.478B | ||
| UCB | UCB SA | 25.91 | 50.767B | ||
| UNC | UCB SA | 25.35 | 50.709B | ||
| BAYN | BAYER AG-REG | 9.24 | 44.474B | ||
| 1BAYN | BAYER AG-REG | 9.26 | 44.435B | ||
| IPN | IPSEN | 11.99 | 11.406B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.61 | 10.021B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About B8FK.DE
Company Profile
Biofrontera AG engages in the research, development, and marketing of dermatological products. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 76 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Company Info
BIOFRONTERA AG
Hemmelrather Weg 201
Leverkusen NORDRHEIN-WESTFALEN DE
Employees: 76
Phone: 49214876320
BIOFRONTERA AG / B8FK.DE FAQ
What does BIOFRONTERA AG do?
Biofrontera AG engages in the research, development, and marketing of dermatological products. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 76 full-time employees. The company went IPO on 2006-10-30. The firm develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The firm is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The firm operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Can you provide the latest stock price for BIOFRONTERA AG?
The current stock price of B8FK.DE is 2.38 EUR. The price decreased by -0.83% in the last trading session.
Does B8FK stock pay dividends?
B8FK.DE does not pay a dividend.
What is the ChartMill rating of BIOFRONTERA AG stock?
B8FK.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy B8FK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on B8FK.DE.
Is BIOFRONTERA AG (B8FK.DE) expected to grow?
The Revenue of BIOFRONTERA AG (B8FK.DE) is expected to grow by 22.18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.